The Federal Trade Commission and four U.S. states have filed a lawsuit against the World Professional Association for Transgender Health (WPATH) regarding the dissemination of medical guidelines for minors.

聯邦貿易委員會與四個美國州政府就傳播未成年人醫療指南的問題，對世界跨性別健康專業協會 (WPATH) 提起訴訟。

The litigation, joined by the states of Alaska, Iowa, Nebraska, and Texas, posits that WPATH disseminated deceptive information concerning the efficacy, safety, and necessity of medical interventions for transgender minors, specifically citing puberty blockers, cross-sex hormones, and surgical procedures. Central to the FTC's contention is the assertion that WPATH failed to provide adequate disclosure regarding potential adverse effects and that the organization excised age-based recommendations from its Standards of Care. FTC Chairman Andrew Ferguson characterized the organization's conduct as a prioritization of financial gain over the health and safety of pediatric patients.

此項訴訟由阿拉斯加州、愛荷華州、內布拉斯加州與德州共同參與，主張 WPATH 傳播了關於跨性別未成年人醫療干預（特別是青春期阻斷劑、跨性別激素與手術程序）之功效、安全性與必要性的誤導性資訊。聯邦貿易委員會 (FTC) 主張的核心在於 WPATH 未能就潛在副作用提供足夠披露，且該組織從其「護理標準」中刪除了基於年齡的建議。FTC 主席 Andrew Ferguson 將該組織的行為描述為將經濟利益置於小兒科患者的健康與安全之上。

This legal maneuver occurs within a broader administrative effort by the Trump administration to scrutinize gender-affirming care. The FTC has similarly initiated investigations into the Endocrine Society and the American Academy of Pediatrics, both of which have pursued legal recourse. Prior to this suit, a federal judge granted a temporary injunction in May to block an FTC probe into WPATH, following the organization's claim that such investigations constituted a violation of First Amendment protections.

此次法律行動發生在川普政府審查性別肯定治療之更廣泛行政努力的背景下。FTC 同樣對內分泌學會 (Endocrine Society) 與美國兒科學會 (American Academy of Pediatrics) 展開調查，兩者均已尋求法律救濟。在此次起訴前，一名聯邦法官於 5 月頒布臨時禁令，以阻止 FTC 對 WPATH 的調查，此前該組織聲稱此類調查構成對第一修正案保障的侵害。

In response to these allegations, WPATH maintains that its guidelines are predicated on expert consensus and scientific standards designed to facilitate individualized patient care rather than standardized protocols. The organization has characterized the current legal action as a retaliatory measure and a targeted campaign intended to undermine the independence of professional medical bodies and infringe upon constitutional rights.

針對這些指控，WPATH 主張其指南是基於專家共識與科學標準，旨在促進個體化的患者護理而非標準化方案。該組織將目前的法律行動定調為報復性措施，以及旨在削弱專業醫療團體獨立性並侵犯憲法權利的針對性運動。

The legal dispute remains ongoing as WPATH seeks to defend its clinical standards against federal and state allegations of deception.

法律爭議仍在持續，WPATH 試圖捍衛其臨床標準，以對抗聯邦與各州關於誤導的指控。